Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Chloropyramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.97 |
| ▸ | DRD1 known ✓ | P21728 | 4/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 4/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 4/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.97 |
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.76 |
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.76 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.76 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.76 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.76 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.70 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.70 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.70 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloropyramine SCHEMBL34463428 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1PTK2CYP2D6CHRM2 | |
| Chloropyramine SCHEMBL30021 | 0.99 | CYP2D6 (1.00) | KDM4EALDH1A1PTK2CYP2D6CHRM2 | |
| Chloropyramine SCHEMBL30566745 | 0.99 | CYP2D6 (1.00) | KDM4EALDH1A1PTK2CYP2D6CHRM2 | |
| Chloropyramine SCHEMBL13723581 | 0.96 | CYP2D6 (0.95) | KDM4EALDH1A1PTK2CYP2D6CHRM2 | |
| SCHEMBL14980581 | 0.90 | CYP2D6 (0.85) | KDM4EALDH1A1PTK2CYP2D6CHRM2 | |
| Tripelennamine SCHEMBL29363256 | 0.88 | KDM4E (1.00) | KDM4EALDH1A1PTK2CYP2D6CHRM2 | |
| Tripelennamine SCHEMBL98916 | 0.88 | KDM4E (1.00) | KDM4EALDH1A1PTK2CYP2D6CHRM2 | |
| Chloropyramine SCHEMBL20770725 | 0.87 | CYP2D6 (0.78) | KDM4EALDH1A1PTK2CYP2D6CHRM2 | |
| Tripelennamine SCHEMBL17970 | 0.87 | CHRM2 (1.00) | KDM4EALDH1A1PTK2CYP2D6CHRM2 | |
| Tripelennamine SCHEMBL29600775 | 0.87 | CHRM2 (1.00) | KDM4EALDH1A1PTK2CYP2D6CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11679113-B2 | Anticancer treatment for uveal melanoma | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-20 | — | — | US | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| US-20200323863-A1 | ANTICANCER TREATMENT FOR UVEAL MELANOMA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-10-15 | — | — | US | claimed |
| US-20190040448-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | THE GENERAL HOSPITAL CORPORATION | 2019-02-07 | — | — | US | claimed |
| US-20160251696-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | TUFTS MEDICAL CENTER | 2016-09-01 | — | — | US | claimed |
| WO-2015054477-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | THE GENERAL HOSPITAL CORPORATION (US) | 2015-04-16 | — | — | WO | claimed |
| US-20140194477-A1 | KINASE PROTEIN BINDING INHIBITORS | ROSWELL PARK CANCER INSTITUTE (US) | 2014-07-10 | — | — | US | claimed |
| WO-2012139001-A2 | KINASE PROTEIN BINDING INHIBITORS | ROSWELL PARK CANCER INSTITUTE (US) | 2012-10-11 | — | — | WO | claimed |
| US-20110224141-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2011-09-15 | — | — | US | claimed |
| WO-2009148623-A2 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2009-12-10 | — | — | WO | claimed |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | UNIV CALIFORNIA (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4696377-A2 | 5HT AGONISTS FOR TREATING DISORDERS | The Regents of the University of California (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4043016-B1 | THE 5HT AGONIST CLEMIZOLE FOR USE IN TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12447144-B2 | 5HT agonists for treating disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-21 | — | — | US | disclosed |
| EP-1438942-A1 | An otorhinological drug delivery device | Schering Oy (FI) | 2004-07-21 | — | — | EP | disclosed |
| US-5478365-A | Combustible heavy hydrocarbon in water emulsion containing nitrogen base neutralized phosphate ester emulsifier, high molecular weight water soluble thickener/stabilizer, water, spherical particles of high softening point hydrocarbon | CHEVRON U.S.A. INC. (US) | 1995-12-26 | — | — | US | disclosed |
| US-4647599-A | Sustained release pharmaceutical tablets and process for the preparation thereof | EGYT GYOGYSZERVEGYESZETI CYAR (HU) | 1987-03-03 | — | — | US | disclosed |
| US-4211764-A | Gastric secretion stimulation with 2-amino-5-(2-aminoethyl)-1,3,4-thiadiozole | NAUCHNO-ISSLEDOVATELSKY INSTITUT EXPERIMENTALNOI MEDITSINY (SU) | 1980-07-08 | — | — | US | disclosed |
| US-4038402-A | METHOD OF EFFECTING ANTIHISTAMINIC, ANTISEROTONIN AND ANTIALLERGIC ACTIONS | KAMINKA MIKHAIL EMMANUILOVICH | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040448-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PTK2, BLK, BCL3 | CHRM2 4879/4885ADRA2A 4456/4885DRD1 4710/4885 |
| US-20260083706-A1 | 5HT AGONISTS FOR TREATING DISORDERS | SLC6A4, SLC6A2, TPH2 | CHRM2 207/4885ADRA2A 144/4885DRD1 342/4885 |
| US-20160251696-A1 | METHODS OF DIAGNOSING AND TREATING B CELL ACUTE LYMPHOBLASTIC LEUKEMIA | PTK2, BLK, BCL3 | CHRM2 4879/4885ADRA2A 4456/4885DRD1 4710/4885 |
| US-12447144-B2 | 5HT agonists for treating disorders | HTR1A, HTR5A, HTR2A | CHRM2 357/4885ADRA2A 37/4885DRD1 178/4885 |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | SLC6A13, SLC6A11, SLC6A1 | CHRM2 1827/4885ADRA2A 1422/4885DRD1 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.